San Diego biotechs support market-rights rule in follow-on biologics bill

05/19/2009 | San Diego Business Journal

The California Healthcare Institute and other members of San Diego's biotech community expressed their support for a measure that would give biotech drugmakers a minimum of 12 years of market exclusivity before generic counterparts of their products can be launched. "The industry now sees this as an inevitable part of its evolution and is concerned about the specifics of the products," CHI President and CEO David Gollaher said.

View Full Article in:

San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC